Association between the 21-Gene Recurrence Score and Benefit from Adjuvant Paclitaxel in Node-Positive, ER-Positive Breast Cancer


Association between the 21-Gene Recurrence Score and Benefit from Adjuvant Paclitaxel in Node-Positive, ER-Positive Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Lisa A Carey, MD (1/17/13)

Mamounas EP et al. Association between the 21-gene Recurrence Score (RS) and benefit from addition of adjuvant paclitaxel in node-positive, ER-positive breast cancer patients: Results from NSABP B-28. San Antonio Breast Cancer Symposium 2012;Abstract S1-10.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.